Best in 7 days Pharmacokinetic profiles after sc administration of 1 mol/kg hGRF 1-29 US$ 26.03 Sold : Login>>
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial US$ 24.31 Min. order: 1 piece ★★★★★ 4.8 (155 reviews) Sold : Login>>
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 US$ 22.39 Min. order: 1 piece ★★★★★ 4.1 (299 reviews) Sold : Login>>
Clinical trials of subcutaneous tirzepatide, retatrutide, and US$ 21.00 Min. order: 1 piece ★★★★★ 4.8 (106 reviews) Sold : Login>>
In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results US$ 26.31 Min. order: 1 piece ★★★★★ 4.1 (252 reviews) Sold : Login>>
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. ➡️ CagriSema, which includes a nascent form of weight loss US$ 27.53 Min. order: 1 piece ★★★★★ 4.3 (186 reviews) Sold : Login>>